I suspect the quantum of the capital raise may be increased as a...

I suspect the quantum of the capital raise may be increased as a result given the CEO comment

Chief Executive Officer, Mr Phillip Lynch said, “This additional result further underscores
the potential patient utility and commercial applicability for Zantrene. We will be allocating
additional resources to ensure this discovery can be comprehensively addressed.”

I suspect if the majority of the shareholders understand the magnitude of todays announcement (and previous announcements) that the SPP will still be heavily oversubscribed even with an increased amount.

It's amazing how you can find money when you need to!